{"id":"exenatide-twice-daily","safety":{"boxedWarning":"Risk of thyroid C-cell tumors observed in rodent studies; relevance to humans unknown","commonSideEffects":["nausea","vomiting","diarrhea","headache","hypoglycemia (when combined with sulfonylureas)"],"contraindications":["personal or family history of medullary thyroid carcinoma","multiple endocrine neoplasia syndrome type 2","severe gastrointestinal disease"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"GLP-1 receptor","explanation":"Exenatide is a synthetic version of exendin-4, a peptide found in Gila monster saliva. It binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating insulin release only when blood glucose is elevated. It also slows gastric emptying and reduces appetite, contributing to weight loss.","oneSentence":"Exenatide activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon release."},"_scrapedAt":"2026-03-28T01:11:58.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122624,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"liraglutide","brand":"Victoza","company":"Novo Nordisk","rationale":"Once-daily GLP-1 receptor agonist for type 2 diabetes"},{"name":"dulaglutide","brand":"Trulicity","company":"Eli Lilly","rationale":"Once-weekly GLP-1 receptor agonist for type 2 diabetes"},{"name":"semaglutide","brand":"Ozempic","company":"Novo Nordisk","rationale":"Once-weekly GLP-1 receptor agonist with superior efficacy"}],"description":"Exenatide twice daily is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus. It mimics the effects of the incretin hormone GLP-1, enhancing insulin secretion in a glucose-dependent manner and suppressing glucagon release.","indications":{"approved":[{"status":"approved","condition":"Type 2 diabetes mellitus","patientPopulation":"Adults as adjunct to diet and exercise"}]},"trialDetails":[{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT01364584","phase":"NA","title":"Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT01416649","phase":"","title":"Impact of Exenatide on Sleep Duration","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-02-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Pre-diabetes, Type 2 Diabetes","enrollment":47},{"nctId":"NCT04969627","phase":"PHASE4","title":"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","status":"COMPLETED","sponsor":"Bing He","startDate":"2021-01-04","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03287076","phase":"PHASE2","title":"Trial of EXenatide in Acute Ischaemic Stroke","status":"UNKNOWN","sponsor":"Neuroscience Trials Australia","startDate":"2017-11-23","conditions":"Acute Ischemic Stroke","enrollment":350},{"nctId":"NCT01590433","phase":"PHASE4","title":"Weight Loss With Exenatide Treatment","status":"COMPLETED","sponsor":"Jody Dushay","startDate":"2012-03","conditions":"Obesity","enrollment":249},{"nctId":"NCT03361098","phase":"PHASE4","title":"DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2017-09-18","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":65},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT00658021","phase":"PHASE3","title":"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05-30","conditions":"Type 2 Diabetes","enrollment":122},{"nctId":"NCT02793154","phase":"PHASE4","title":"An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT00799435","phase":"PHASE4","title":"Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2, Heart Failure, Diastolic","enrollment":2},{"nctId":"NCT04303819","phase":"","title":"The Effect of Exenatide on Fasting Bile Acids","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2020-01-05","conditions":"Type 2 Diabetes Mellitus in Obese","enrollment":38},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT01061775","phase":"PHASE1, PHASE2","title":"Effects of Exenatide on Hypothalamic Obesity","status":"COMPLETED","sponsor":"Children's Hospitals and Clinics of Minnesota","startDate":"2010-01","conditions":"Hypothalamic Obesity","enrollment":19},{"nctId":"NCT03352869","phase":"PHASE4","title":"Research of Exenatide for Overweight/Obese PCOS Patients With IGR","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-11-28","conditions":"Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation","enrollment":183},{"nctId":"NCT02303730","phase":"PHASE4","title":"Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease","enrollment":76},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00856609","phase":"PHASE3","title":"The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2009-03-03","conditions":"Weight Loss, Obesity","enrollment":150},{"nctId":"NCT01687582","phase":"NA","title":"Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2012-01","conditions":"Type 2 Diabetes, Psoriasis","enrollment":10},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02860923","phase":"PHASE3","title":"Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2017-01-11","conditions":"Craniopharyngiomas, Hypothalamic Obesity","enrollment":42},{"nctId":"NCT01136798","phase":"NA","title":"Impact of Exenatide on Sleep in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-06-01","conditions":"Type 2 Diabetes, Sleep Disordered Breathing","enrollment":18},{"nctId":"NCT01652716","phase":"PHASE3","title":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-01","conditions":"Diabetes Mellitus, Type 2","enrollment":377},{"nctId":"NCT00845507","phase":"PHASE4","title":"Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-12","conditions":"Weight Gain","enrollment":54},{"nctId":"NCT02735031","phase":"PHASE2, PHASE3","title":"Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-02-21","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia","enrollment":10},{"nctId":"NCT01255163","phase":"PHASE2","title":"A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease","status":"TERMINATED","sponsor":"National Institute on Aging (NIA)","startDate":"2010-11-21","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":57},{"nctId":"NCT00845182","phase":"PHASE4","title":"Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2007-06","conditions":"Type 2 Diabetes, Healthy, Impaired Glucose Tolerance","enrollment":43},{"nctId":"NCT00353834","phase":"PHASE4","title":"The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT00456885","phase":"PHASE4","title":"The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2007-04","conditions":"Obesity, Impaired Glucose Tolerance","enrollment":41},{"nctId":"NCT03239119","phase":"PHASE3","title":"The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-11-30","conditions":"Type2 Diabetes Mellitus","enrollment":456},{"nctId":"NCT01381926","phase":"PHASE4","title":"Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus, Bone Remodeling","enrollment":14},{"nctId":"NCT01089569","phase":"NA","title":"Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-04","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00650546","phase":"PHASE2, PHASE3","title":"Role of Exenatide in NASH-a Pilot Study","status":"COMPLETED","sponsor":"Indiana University","startDate":"2006-08","conditions":"Nonalcoholic Fatty Liver Disease","enrollment":8},{"nctId":"NCT02987348","phase":"","title":"Clinical Outcomes of Exenatide Versus Basal Insulin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-30","conditions":"Type 2 Diabetes","enrollment":18000},{"nctId":"NCT00518882","phase":"PHASE3","title":"Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":467},{"nctId":"NCT01484873","phase":"PHASE2","title":"Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2012-06","conditions":"Obesity, Overweight, Craniopharyngioma","enrollment":10},{"nctId":"NCT00855439","phase":"NA","title":"Evaluation of Exenatide in Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy","enrollment":46},{"nctId":"NCT03059719","phase":"PHASE1","title":"Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2015-04-08","conditions":"Type II Diabetes Mellitus","enrollment":36},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT02170324","phase":"PHASE4","title":"GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men","status":"COMPLETED","sponsor":"Xiang Guang-da","startDate":"2014-06","conditions":"Obesity","enrollment":20},{"nctId":"NCT03018665","phase":"PHASE4","title":"A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-02","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00518115","phase":"PHASE2","title":"Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Diabetes Mellitus, Type 2","enrollment":361},{"nctId":"NCT00707031","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":639},{"nctId":"NCT00717457","phase":"PHASE3","title":"A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Diabetes Mellitus Type 2","enrollment":1189},{"nctId":"NCT00765817","phase":"PHASE3","title":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":261},{"nctId":"NCT01444898","phase":"NA","title":"Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2012-03","conditions":"Prader-Willi Syndrome","enrollment":10},{"nctId":"NCT01006889","phase":"PHASE4","title":"Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-01","conditions":"Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02160990","phase":"PHASE4","title":"Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-06","conditions":"Obesity","enrollment":20},{"nctId":"NCT01235819","phase":"PHASE4","title":"Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Command Hospital, India","startDate":"2010-11","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT01951651","phase":"PHASE4","title":"Effect of Exenatide on Liver and Heart Fat and Inflammation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-04","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01432405","phase":"PHASE4","title":"Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00803920","phase":"","title":"Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2006-12","conditions":"Type 2 Diabetes Mellitus","enrollment":8},{"nctId":"NCT02584075","phase":"PHASE4","title":"Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2015-11","conditions":"Coronary Endothelial Function","enrollment":100},{"nctId":"NCT02584582","phase":"PHASE2, PHASE3","title":"The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2015-07","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00359762","phase":"PHASE3","title":"Exenatide Versus Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1029},{"nctId":"NCT00477581","phase":"PHASE4","title":"A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT00308139","phase":"PHASE3","title":"Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":303},{"nctId":"NCT00254800","phase":"PHASE1","title":"The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Type 2 Diabetes Mellitus","enrollment":38},{"nctId":"NCT00943917","phase":"PHASE2","title":"Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":155},{"nctId":"NCT00701935","phase":"PHASE2","title":"Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Diabetes Mellitus","enrollment":80},{"nctId":"NCT00635492","phase":"","title":"CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":2515},{"nctId":"NCT00729326","phase":"PHASE4","title":"Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":83},{"nctId":"NCT00917267","phase":"PHASE3","title":"A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Type 2 Diabetes Mellitus","enrollment":691},{"nctId":"NCT00870194","phase":"PHASE4","title":"A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":255},{"nctId":"NCT00577824","phase":"PHASE3","title":"Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":181},{"nctId":"NCT01060059","phase":"","title":"Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Type 2 Diabetes Mellitus","enrollment":888},{"nctId":"NCT00434954","phase":"PHASE3","title":"Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Type 2 Diabetes Mellitus","enrollment":494},{"nctId":"NCT00082381","phase":"PHASE3","title":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Diabetes Mellitus, Type 2","enrollment":551},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT00082407","phase":"PHASE3","title":"Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Diabetes Mellitus, Type 2","enrollment":505},{"nctId":"NCT01003184","phase":"PHASE3","title":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":222},{"nctId":"NCT00603239","phase":"PHASE3","title":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":165},{"nctId":"NCT00516048","phase":"PHASE3","title":"An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT00516074","phase":"PHASE3","title":"A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT00877890","phase":"PHASE3","title":"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":254},{"nctId":"NCT00360334","phase":"PHASE3","title":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT00135330","phase":"PHASE3","title":"An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":137},{"nctId":"NCT00500370","phase":"PHASE2","title":"A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Obesity","enrollment":163},{"nctId":"NCT00375492","phase":"PHASE3","title":"Effect on Weight Loss of Exenatide Versus Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes Mellitus","enrollment":196},{"nctId":"NCT00064714","phase":"PHASE2","title":"Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":"Diabetes Mellitus","enrollment":47},{"nctId":"NCT00039013","phase":"PHASE3","title":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-03","conditions":"Diabetes Mellitus, Type 2","enrollment":336},{"nctId":"NCT00103935","phase":"PHASE2","title":"Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-02","conditions":"Type 2 Diabetes Mellitus","enrollment":45},{"nctId":"NCT00035984","phase":"PHASE3","title":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":734},{"nctId":"NCT01789957","phase":"PHASE3","title":"Extension Study for 2993-112","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"Type 2 Diabetes Mellitus","enrollment":225},{"nctId":"NCT01876849","phase":"PHASE3","title":"An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Type 2 Diabetes Mellitus","enrollment":275},{"nctId":"NCT00039026","phase":"PHASE3","title":"Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-02","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":377},{"nctId":"NCT00241423","phase":"PHASE2","title":"Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00099320","phase":"PHASE3","title":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Type 2 Diabetes Mellitus","enrollment":182},{"nctId":"NCT00099333","phase":"PHASE2","title":"Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-02","conditions":"Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT00111540","phase":"PHASE3","title":"Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-11","conditions":"Diabetes Mellitus, Type 2","enrollment":456},{"nctId":"NCT00085969","phase":"PHASE2","title":"Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Diabetes Mellitus, Type 2","enrollment":99},{"nctId":"NCT00517283","phase":"PHASE1","title":"A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-01","conditions":"Type 2 Diabetes Mellitus","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":161,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Byetta","BYETTA","short-acting glucagon-like peptide-1 receptor agonist"],"phase":"phase_3","status":"active","brandName":"exenatide twice daily","genericName":"exenatide twice daily","companyName":"AstraZeneca","companyId":"astrazeneca","firstApprovalDate":"","aiSummary":"Exenatide is a medication used to treat conditions such as Type 2 Diabetes Mellitus. It is administered twice daily, typically in the form of BYETTA, to help manage blood sugar levels.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}